

## Consumer Healthcare turnover

Three months ended 30 September 2013

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
Total wellness	482	-	(3)
Oral care	476	6	5
Nutrition	290	10	5
Skin health	65	-	-
Total	1,313	4	2

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
US	233	-	3
Europe	473	6	9
ROW	607	4	3
Total	1,313	4	2

Nine months ended 30 September 2013

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
Total wellness	1,466	(4)	(4)
Oral care	1,437	6	6
Nutrition	861	8	6
Skin health	205	6	7
Total	3,969	2	2

	Total		
	£m	CER%	AR%
<b>Turnover</b>			
US	709	3	5
Europe	1,384	-	2
ROW	1,876	4	-
Total	3,969	2	2

Pharmaceuticals and Vaccines turnover – Three months ended 30 September 2013

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>1,693</b>	<b>(2)</b>	<b>(2)</b>	<b>830</b>	<b>(3)</b>	<b>(1)</b>	<b>441</b>	<b>(2)</b>	<b>3</b>	<b>191</b>	<b>(5)</b>	<b>(8)</b>	<b>231</b>	<b>3</b>	<b>(10)</b>
<i>Avamys/Veramyst</i>	55	8	4	13	(14)	(7)	13	8	8	20	31	25	9	-	(18)
<i>Flixonase/Flonase</i>	19	(29)	(32)	-	-	-	7	-	-	11	(33)	(27)	1	(25)	(75)
<i>Flixotide/Flovent</i>	172	(7)	(7)	105	(8)	(6)	25	(4)	-	12	-	-	30	(8)	(17)
<i>Seretide/Advair</i>	1,209	(1)	(1)	632	(1)	1	344	(1)	3	87	(12)	(14)	146	7	(5)
<i>Serevent</i>	32	(6)	(6)	13	8	8	13	(25)	(19)	1	-	-	5	20	-
<i>Ventolin</i>	145	(5)	(5)	66	(10)	(8)	29	-	4	39	3	-	11	(8)	(15)
<i>Xyzal</i>	25	24	-	-	-	-	-	-	-	4	(40)	(20)	21	40	5
<i>Zyrtec</i>	15	-	(12)	-	-	-	-	-	-	9	25	13	6	(22)	(33)
Other*	21	(17)	(9)	1	-	-	10	-	25	8	-	(27)	2	<(100)	(50)
<b>Anti-virals</b>	<b>124</b>	<b>(22)</b>	<b>(27)</b>	<b>18</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>17</b>	<b>(11)</b>	<b>(6)</b>	<b>47</b>	<b>(51)</b>	<b>(49)</b>	<b>42</b>	<b>(7)</b>	<b>(25)</b>
<i>Hepsera</i>	15	(47)	(53)	-	-	-	-	-	-	10	(63)	(58)	5	-	(38)
<i>Valtrex</i>	55	17	6	10	-	-	8	-	14	11	-	-	26	(6)	(24)
<i>Zovirax</i>	20	(5)	(5)	-	-	-	5	(20)	-	8	13	-	7	-	-
<i>Zeffix</i>	27	(57)	(56)	3	(25)	(25)	3	(25)	(25)	16	(69)	(67)	5	-	-
Other*	7	>100	>100	5	>100	>100	1	-	(50)	2	-	-	(1)	(100)	<(100)
<b>Central nervous system</b>	<b>364</b>	<b>(5)</b>	<b>(9)</b>	<b>109</b>	<b>(12)</b>	<b>(11)</b>	<b>87</b>	<b>(10)</b>	<b>(5)</b>	<b>82</b>	<b>5</b>	<b>.</b>	<b>86</b>	<b>2</b>	<b>(17)</b>
<i>Imigran/Imitrex</i>	47	2	-	21	18	24	15	(6)	(6)	1	-	(50)	10	(8)	(17)
<i>Lamictal</i>	139	(6)	(8)	70	(16)	(14)	27	(4)	-	19	-	(5)	23	22	-
<i>Requip</i>	36	(5)	(10)	3	-	-	13	(37)	(32)	4	-	-	16	36	14
<i>Seroxat/Paxil</i>	64	(9)	(20)	-	-	-	12	(8)	(8)	16	(16)	(16)	36	(6)	(25)
<i>Wellbutrin</i>	23	-	5	1	(60)	(80)	12	9	9	7	(13)	(13)	3	>100	>100
Other*	55	(2)	(7)	14	(13)	(13)	8	-	33	35	28	21	(2)	(88)	<(100)
<b>Cardiovascular and urogenital</b>	<b>539</b>	<b>(4)</b>	<b>(4)</b>	<b>300</b>	<b>(9)</b>	<b>(7)</b>	<b>129</b>	<b>3</b>	<b>9</b>	<b>64</b>	<b>(12)</b>	<b>(15)</b>	<b>46</b>	<b>20</b>	<b>5</b>
<i>Arixtra</i>	40	(17)	(15)	13	(28)	(28)	20	(14)	(5)	5	-	(17)	2	-	-
<i>Avodart</i>	207	6	4	73	(11)	(10)	67	17	24	26	13	13	41	20	-
<i>Coreg</i>	36	9	13	36	9	13	-	-	-	-	-	-	-	-	-
<i>Fraxiparine</i>	53	(7)	(2)	-	-	-	33	3	6	19	(14)	(14)	1	<(100)	-
<i>Lovaza</i>	135	(12)	(11)	134	(12)	(11)	-	-	-	-	-	-	1	-	-
Other*	68	(10)	(12)	44	2	5	9	(25)	(25)	14	(38)	(42)	1	>100	>100
<b>Metabolic</b>	<b>41</b>	<b>2</b>	<b>(7)</b>	<b>1</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>10</b>	<b>43</b>	<b>43</b>	<b>16</b>	<b>(6)</b>	<b>(6)</b>	<b>14</b>	<b>(14)</b>	<b>(33)</b>
Other*	41	2	(7)	1	>100	>100	10	43	43	16	(6)	(6)	14	(14)	(33)
<b>Anti-bacterials</b>	<b>282</b>	<b>(2)</b>	<b>(2)</b>	<b>8</b>	<b>80</b>	<b>60</b>	<b>85</b>	<b>(1)</b>	<b>4</b>	<b>171</b>	<b>(2)</b>	<b>(5)</b>	<b>18</b>	<b>(18)</b>	<b>(18)</b>
<i>Augmentin</i>	140	1	1	-	-	-	43	5	13	90	1	(2)	7	-	(13)
Other*	142	(5)	(5)	8	>100	100	42	(7)	(5)	81	(6)	(8)	11	(29)	(21)
<b>Oncology and emesis</b>	<b>249</b>	<b>23</b>	<b>22</b>	<b>99</b>	<b>14</b>	<b>18</b>	<b>91</b>	<b>32</b>	<b>40</b>	<b>36</b>	<b>19</b>	<b>16</b>	<b>23</b>	<b>29</b>	<b>(4)</b>
<i>Arzerra</i>	18	(11)	(5)	13	20	30	4	(50)	(50)	-	-	-	1	-	-
<i>Promacta</i>	49	43	40	19	27	27	15	56	67	6	100	100	9	38	13
<i>Tyverb/Tykerb</i>	53	(7)	(7)	14	(18)	(18)	21	(10)	-	12	8	-	6	-	(14)
<i>Votrient</i>	91	84	86	36	38	38	39	>100	>100	10	100	100	6	>100	>100
Other*	38	(9)	(14)	17	(6)	6	12	10	20	8	(27)	(27)	1	(14)	(86)
<b>Dermatology</b>	<b>194</b>	<b>(1)</b>	<b>(4)</b>	<b>40</b>	<b>(18)</b>	<b>(18)</b>	<b>42</b>	<b>3</b>	<b>5</b>	<b>96</b>	<b>9</b>	<b>2</b>	<b>16</b>	<b>(11)</b>	<b>(17)</b>
<i>Bactroban</i>	26	(16)	(19)	9	(38)	(31)	6	(29)	(14)	11	10	10	-	-	-
<i>Duac</i>	18	20	20	4	(20)	(20)	7	-	-	4	67	33	3	-	-
Other*	150	-	(3)	27	(10)	(13)	29	12	12	81	8	1	13	(35)	(29)
<b>Rare diseases</b>	<b>125</b>	<b>(1)</b>	<b>(9)</b>	<b>30</b>	<b>(26)</b>	<b>(23)</b>	<b>32</b>	<b>7</b>	<b>10</b>	<b>13</b>	<b>-</b>	<b>(7)</b>	<b>50</b>	<b>11</b>	<b>(9)</b>
<i>Volibris</i>	36	15	9	-	-	-	21	5	11	3	(33)	-	12	45	9
<i>Flolan</i>	25	(10)	(19)	5	(38)	(38)	4	25	-	-	-	-	16	(5)	(16)
Other*	64	(5)	(12)	25	(23)	(19)	7	-	17	10	9	(9)	22	8	(12)
<b>Immuno-inflammation</b>	<b>48</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>45</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>2</b>	<b>100</b>	<b>100</b>	<b>1</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<i>Benlysta</i>	42	>100	>100	39	100	>100	2	100	100	1	-	-	-	-	-
Other*	6	-	-	6	-	-	-	-	-	-	-	-	-	-	-
<b>Other pharmaceuticals</b>	<b>207</b>	<b>13</b>	<b>8</b>	<b>1</b>	<b>(98)</b>	<b>(91)</b>	<b>65</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>88</b>	<b>(8)</b>	<b>(15)</b>	<b>53</b>	<b>23</b>	<b>10</b>
<b>Vaccines</b>	<b>987</b>	<b>3</b>	<b>5</b>	<b>375</b>	<b>24</b>	<b>27</b>	<b>273</b>	<b>4</b>	<b>10</b>	<b>263</b>	<b>(14)</b>	<b>(13)</b>	<b>76</b>	<b>(14)</b>	<b>(19)</b>
<i>Boostrix</i>	83	4	6	56	(2)	-	18	21	29	4	33	33	5	-	-
<i>Cervarix</i>	41	(11)	(9)	2	(33)	(33)	14	27	27	25	32	32	-	-	-
<i>Fluarix, FluLaval</i>	142	1	3	104	29	32	16	(16)	(16)	7	(69)	(73)	15	(7)	7
Hepatitis	168	(1)	-	81	5	8	48	(4)	2	29	(15)	(15)	10	8	(17)
<i>Infanrix, Pediarix</i>	258	26	29	100	69	72	98	1	8	44	26	26	16	6	-
<i>Rotarix</i>	108	5	5	32	19	23	17	78	89	50	2	4	9	(40)	(55)
<i>Synflorix</i>	80	(28)	(25)	-	-	-	12	(8)	-	66	(32)	(29)	2	100	100
Other*	107	4	5	-	-	-	50	2	9	38	(12)	(12)	19	43	36
	<b>4,853</b>	<b>-</b>	<b>(1)</b>	<b>1,856</b>	<b>2</b>	<b>4</b>	<b>1,274</b>	<b>5</b>	<b>10</b>	<b>1,068</b>	<b>(9)</b>	<b>(11)</b>	<b>655</b>	<b>2</b>	<b>(17)</b>
<b>ViiV Healthcare (HIV)</b>	<b>344</b>	<b>(5)</b>	<b>(3)</b>												
	<b>5,197</b>	<b>-</b>	<b>(1)</b>												

Pharmaceuticals and Vaccines turnover – Nine months ended 30 September 2013

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<b>Respiratory</b>	<b>5,534</b>	<b>3</b>	<b>3</b>	<b>2,680</b>	<b>4</b>	<b>6</b>	<b>1,424</b>	<b>(2)</b>	<b>1</b>	<b>639</b>	<b>4</b>	<b>3</b>	<b>791</b>	<b>5</b>	<b>(5)</b>
<i>Avamys/Veramyst</i>	195	8	5	36	(19)	(16)	53	4	8	53	20	18	53	24	8
<i>Flixonase/Flonase</i>	85	(13)	(16)	3	(73)	(73)	24	-	-	39	(7)	(5)	19	(8)	(24)
<i>Flixotide/Flovent</i>	587	2	2	358	6	8	87	(7)	(3)	41	5	5	101	(4)	(10)
<i>Seretide/Advair</i>	3,876	3	4	2,028	5	7	1,090	(1)	2	310	3	4	448	5	(4)
<i>Serevent</i>	98	(11)	(11)	38	-	-	41	(18)	(16)	3	50	50	16	(19)	(24)
<i>Ventolin</i>	467	2	3	211	5	7	94	-	3	124	1	-	38	(2)	(7)
<i>Xyzal</i>	101	27	9	-	-	-	-	-	-	13	(8)	-	88	33	10
<i>Zyrtec</i>	56	5	(5)	-	-	-	-	-	-	30	24	20	26	(9)	(24)
Other*	69	(9)	(8)	6	-	20	35	(11)	(8)	26	(6)	(16)	2	(100)	100
<b>Anti-virals</b>	<b>465</b>	<b>(12)</b>	<b>(15)</b>	<b>40</b>	<b>50</b>	<b>54</b>	<b>50</b>	<b>(20)</b>	<b>(17)</b>	<b>222</b>	<b>(18)</b>	<b>(16)</b>	<b>153</b>	<b>(9)</b>	<b>(23)</b>
<i>Hepsera</i>	73	(19)	(22)	-	-	-	-	-	-	55	(26)	(21)	18	-	(22)
<i>Valtrex</i>	165	(1)	(9)	30	100	100	22	(22)	(19)	30	7	7	83	(11)	(25)
<i>Zovirax</i>	61	(6)	(9)	1	(67)	(67)	15	(18)	(12)	25	4	-	20	-	(9)
<i>Zeffix</i>	139	(24)	(22)	10	-	-	9	(31)	(31)	107	(27)	(23)	13	(12)	(24)
Other*	27	-	(10)	(1)	-	50	4	33	33	5	100	67	19	(15)	(27)
<b>Central nervous system</b>	<b>1,099</b>	<b>(9)</b>	<b>(12)</b>	<b>324</b>	<b>(17)</b>	<b>(15)</b>	<b>269</b>	<b>(11)</b>	<b>(8)</b>	<b>251</b>	<b>8</b>	<b>6</b>	<b>255</b>	<b>(11)</b>	<b>(24)</b>
<i>Imigran/Imitrex</i>	142	1	(1)	62	13	15	48	(8)	(6)	5	-	-	27	(6)	(18)
<i>Lamictal</i>	405	(8)	(9)	199	(19)	(17)	82	(6)	(4)	58	5	4	66	20	3
<i>Requip</i>	96	(22)	(26)	6	(67)	(67)	41	(34)	(31)	11	-	-	38	10	(7)
<i>Seroxat/Paxil</i>	216	(17)	(24)	-	-	-	41	(5)	(2)	60	(2)	(2)	115	(25)	(36)
<i>Wellbutrin</i>	71	11	15	10	11	11	37	9	12	22	5	5	2	>100	>100
Other*	169	(7)	(8)	47	(23)	(22)	20	(22)	(13)	95	18	14	7	(50)	(61)
<b>Cardiovascular and urogenital</b>	<b>1,691</b>	<b>(10)</b>	<b>(9)</b>	<b>948</b>	<b>(18)</b>	<b>(17)</b>	<b>398</b>	<b>1</b>	<b>5</b>	<b>214</b>	<b>-</b>	<b>-</b>	<b>131</b>	<b>18</b>	<b>5</b>
<i>Arixtra</i>	134	(8)	(6)	43	(12)	(12)	64	(12)	(7)	22	16	16	5	-	-
<i>Avodart</i>	631	9	8	232	(4)	(3)	201	16	20	77	22	22	121	21	6
<i>Coreg</i>	102	(2)	-	101	(3)	(1)	-	-	-	-	-	-	1	-	-
<i>Fraxiparine</i>	166	(8)	(5)	-	-	-	104	(10)	(6)	62	(2)	-	-	-	-
<i>Lovaza</i>	444	(5)	(3)	442	(5)	(3)	-	-	-	-	-	-	2	-	-
Other*	214	(47)	(47)	130	(57)	(56)	29	(6)	(6)	53	(24)	(25)	2	(33)	(33)
<b>Metabolic</b>	<b>131</b>	<b>13</b>	<b>7</b>	<b>2</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>30</b>	<b>45</b>	<b>50</b>	<b>52</b>	<b>8</b>	<b>6</b>	<b>47</b>	<b>(19)</b>	<b>(30)</b>
Other*	131	13	7	2	>100	>100	30	45	50	52	8	6	47	(19)	(30)
<b>Anti-bacterials</b>	<b>930</b>	<b>2</b>	<b>2</b>	<b>21</b>	<b>40</b>	<b>40</b>	<b>291</b>	<b>(5)</b>	<b>(2)</b>	<b>566</b>	<b>7</b>	<b>6</b>	<b>52</b>	<b>(14)</b>	<b>(19)</b>
<i>Augmentin</i>	465	6	5	-	(100)	(100)	150	(3)	1	292	12	10	23	(7)	(15)
Other*	465	(1)	(1)	21	50	50	141	(8)	(5)	274	3	2	29	(19)	(22)
<b>Oncology and emesis</b>	<b>703</b>	<b>21</b>	<b>21</b>	<b>278</b>	<b>16</b>	<b>18</b>	<b>250</b>	<b>28</b>	<b>33</b>	<b>103</b>	<b>17</b>	<b>14</b>	<b>72</b>	<b>26</b>	<b>9</b>
<i>Arzerra</i>	56	20	22	33	14	18	22	29	29	-	-	-	1	-	-
<i>Promacta</i>	134	48	46	54	36	38	39	48	56	16	100	100	25	50	25
<i>Tyverb/Tykerb</i>	158	(11)	(11)	44	(16)	(14)	63	(9)	(5)	33	(13)	(15)	18	-	(14)
<i>Votrient</i>	241	97	99	105	66	69	95	>100	>100	26	>100	100	15	>100	>100
Other*	114	(20)	(20)	42	(25)	(24)	31	(17)	(14)	28	(7)	(7)	13	(32)	(41)
<b>Dermatology</b>	<b>599</b>	<b>(3)</b>	<b>(4)</b>	<b>119</b>	<b>(30)</b>	<b>(29)</b>	<b>128</b>	<b>9</b>	<b>12</b>	<b>304</b>	<b>9</b>	<b>7</b>	<b>48</b>	<b>(12)</b>	<b>(19)</b>
<i>Bactroban</i>	75	(17)	(18)	22	(43)	(41)	18	(15)	(10)	31	10	7	4	-	(33)
<i>Duac</i>	53	(20)	(20)	11	(66)	(66)	21	17	17	12	44	33	9	14	29
Other*	471	2	1	86	(13)	(12)	89	13	17	261	8	6	35	(17)	(24)
<b>Rare diseases</b>	<b>365</b>	<b>10</b>	<b>3</b>	<b>86</b>	<b>5</b>	<b>8</b>	<b>95</b>	<b>-</b>	<b>3</b>	<b>34</b>	<b>6</b>	<b>3</b>	<b>150</b>	<b>19</b>	<b>1</b>
<i>Volibris</i>	107	21	16	-	-	-	61	7	11	8	14	14	38	47	27
<i>Flolan</i>	80	(14)	(21)	19	(21)	(21)	14	(22)	(22)	-	-	-	47	(8)	(20)
Other*	178	18	11	67	16	20	20	-	5	26	4	-	65	32	10
<b>Immuno-inflammation</b>	<b>115</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>107</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>6</b>	<b>&gt;100</b>	<b>&gt;100</b>	<b>1</b>	<b>-</b>	<b>-</b>	<b>1</b>	<b>100</b>	<b>-</b>
<i>Benlysta</i>	109	>100	>100	101	>100	>100	6	>100	>100	1	-	-	1	100	-
Other*	6	-	-	6	-	-	-	-	-	-	-	-	-	-	-
<b>Other pharmaceuticals</b>	<b>544</b>	<b>2</b>	<b>(2)</b>	<b>2</b>	<b>(71)</b>	<b>(82)</b>	<b>121</b>	<b>(2)</b>	<b>3</b>	<b>271</b>	<b>(4)</b>	<b>(9)</b>	<b>150</b>	<b>24</b>	<b>17</b>
<b>Vaccines</b>	<b>2,453</b>	<b>(2)</b>	<b>-</b>	<b>735</b>	<b>15</b>	<b>17</b>	<b>774</b>	<b>4</b>	<b>8</b>	<b>735</b>	<b>(8)</b>	<b>(7)</b>	<b>209</b>	<b>(35)</b>	<b>(37)</b>
<i>Boostrix</i>	197	5	8	118	2	4	50	23	28	13	18	18	16	(16)	(16)
<i>Cervarix</i>	127	(44)	(44)	5	-	-	42	3	5	67	25	26	13	(89)	(90)
<i>Fluarix, FluLaval</i>	164	7	9	110	35	38	14	(18)	(18)	21	(38)	(38)	19	(5)	-
Hepatitis	477	(3)	(2)	208	(1)	1	146	(4)	(1)	89	(7)	(6)	34	(3)	(11)
<i>Infanrix, Pediarix</i>	654	18	21	210	38	41	297	4	8	100	41	41	47	4	2
<i>Rotarix</i>	275	1	1	84	11	14	44	48	52	118	(5)	(4)	29	(28)	(37)
<i>Synflorix</i>	244	(16)	(13)	-	-	-	36	6	13	203	(19)	(17)	5	25	25
Other*	315	(5)	(3)	-	>100	100	145	2	7	124	(22)	(21)	46	44	44
	<b>14,629</b>	<b>-</b>	<b>-</b>	<b>5,342</b>	<b>-</b>	<b>2</b>	<b>3,836</b>	<b>-</b>	<b>4</b>	<b>3,392</b>	<b>-</b>	<b>(1)</b>	<b>2,059</b>	<b>(2)</b>	<b>(13)</b>
<b>ViiV Healthcare (HIV)</b>	<b>1,001</b>	<b>(5)</b>	<b>(3)</b>												
	<b>15,630</b>	<b>-</b>	<b>(1)</b>												

**ViiV Healthcare turnover**  
**Three months ended 30 September 2013**

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Combivir</i>	25	(55)	(53)	7	11	13	8	(50)	(46)	8	(73)	(73)	2	(33)	(33)
<i>Epivir</i>	12	-	-	3	23	26	3	(25)	(21)	3	13	14	3	50	-
<i>Epzicom/Kivexa</i>	190	8	9	65	(3)	(1)	79	8	14	24	20	19	22	37	16
<i>Selzentry</i>	34	10	13	16	16	18	14	2	7	1	89	84	3	-	50
<i>Trizivir</i>	24	(4)	(4)	15	(1)	1	8	(19)	(14)	2	(4)	(7)	(1)	-	-
<i>Other*</i>	59	(6)	(5)	30	11	18	12	(36)	(29)	13	8	-	4	(43)	(57)
	<b>344</b>	<b>(5)</b>	<b>(3)</b>	<b>136</b>	<b>3</b>	<b>5</b>	<b>124</b>	<b>(7)</b>	<b>(2)</b>	<b>51</b>	<b>(26)</b>	<b>(27)</b>	<b>33</b>	<b>19</b>	<b>6</b>

**Nine months ended 30 September 2013**

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Combivir</i>	85	(39)	(38)	24	58	61	32	(38)	(36)	24	(62)	(62)	5	(38)	(38)
<i>Epivir</i>	34	(13)	(13)	7	20	22	12	(30)	(27)	9	(7)	(5)	6	(14)	(14)
<i>Epzicom/Kivexa</i>	552	9	11	189	1	3	240	9	14	60	30	31	63	23	11
<i>Selzentry</i>	106	16	18	44	8	10	46	8	12	5	>100	95	11	83	83
<i>Trizivir</i>	71	(14)	(12)	42	(8)	(7)	25	(18)	(15)	3	(44)	(46)	1	-	(50)
<i>Other*</i>	153	(21)	(20)	75	(24)	(24)	36	(27)	(20)	29	(5)	(6)	13	(25)	(19)
	<b>1,001</b>	<b>(5)</b>	<b>(3)</b>	<b>381</b>	<b>(4)</b>	<b>(2)</b>	<b>391</b>	<b>(4)</b>	<b>(1)</b>	<b>130</b>	<b>(17)</b>	<b>(17)</b>	<b>99</b>	<b>10</b>	<b>2</b>

\* All "Other" Pharmaceuticals and Vaccines product sales totalled £965 million and increased 1% CER and 2% AR in the quarter and totalled £2,856 million and decreased 7% CER and 8% AR in the nine months. Other Pharmaceuticals turnover includes milestone income received from Theravance of £6 million in Q3 2013 and £25 million in the nine months.